Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Nervous System Diseases | 3 |
Neoplasms | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Hematopoietic stem cell therapy | 3 |
CAR-T | 1 |
Top 5 Target | Count |
---|---|
CD84(CD84 molecule) | 1 |
Target- |
Mechanism Cell replacements [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD84 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Gene transference |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date05 May 2024 |
Sponsor / Collaborator |
Start Date02 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
OTL-204 | Frontotemporal Dementia More | Preclinical |
OTL-205 | Amyotrophic Lateral Sclerosis More | Preclinical |
CD84 Targeted CAR-T(Altheia science) ( CD84 ) | Adult Acute Myeloblastic Leukemia More | Preclinical |
Human iduronate 2-sulfatase stem cell-based gene therapy(University of Padua) | Mucopolysaccharidosis II More | Discovery |
SF 348 ( β-adrenoceptors ) | Heart Failure More | Pending |